Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) With Advanced Stage Diffuse Large B-Cell NHL of Low and Low-Intermediate IPI Risk
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cyclophosphamide; Doxorubicin; Oblimersen; Prednisone; Rituximab; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 07 Jan 2013 Biomarkers information updated
- 12 Jan 2012 Actual patient number (8) added as reported by ClinicalTrials.gov record.
- 12 Jan 2012 Actual end date (1 Jun 2007) added as reported by ClinicalTrials.gov record.